Navigation Links
Bayer HealthCare's Cotavance® Drug Eluting Balloon With Paccocath® Technology Reduced Five-Year Target Lesion Revascularization Rates by 59 Percent in PAD Patients Compared to Those Treated With Uncoated Balloon
Date:11/10/2011

WARRENDALE, Pa., Nov. 10, 2011 /PRNewswire/ -- Bayer HealthCare's affiliate MEDRAD, Inc. today announced that five-year data from the THUNDER trial* demonstrated a 59 percent relative reduction in target lesion revascularization (TLR) rates in popliteal arteries of patients with peripheral arterial disease (PAD) treated with the Cotavance® drug eluting balloon with Paccocath® technology compared to standard balloon angioplasty (POBA). Additionally, for patients requiring TLR, the average time to revascularization before TLR was extended by 448 days in patients treated with the Cotavance catheter, which is available in Europe, but not yet approved in the U.S. MEDRAD is currently moving forward with the Investigational Device Exemption (IDE) process as one of the steps in gaining FDA approval for Cotavance product in the United States.

The data were presented at the 2011 Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation, in San Francisco as part of a TCT-sponsored symposium titled, "Drug-Coated Balloons: Clinical Data and Applications."

"These data with Bayer HealthCare's Paccocath technology represent the only five-year clinical TLR outcomes in comparison to standard balloons," said Prof. Dr. med. Gunnar Tepe of Klinikum Rosenheim in Rosenheim, Germany, principal investigator of THUNDER. "The results demonstrate clear long-term benefits for patients with the Cotavance paclitaxel eluting balloon for reducing the number of TLR procedures and extending the time before a revascularization might be needed in PAD patients." Dr. med. Thomas Zeller of Herz-Zentrum, Bad Krozingen, Germany, who presented the data at the TCT symposium, added, "Beginning as early as the first year and continuing through year five, a consistent 30 to 40 percent improvement was seen with the Cotavance catheter in avoiding TLR. TCT was an excellent venue to share these ground-breaking data."

D
'/>"/>

SOURCE Bayer HealthCare-MEDRAD, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Bayer Broadens Its Manufacturing Basis for Biopharmaceuticals in Tobacco Plants
2. GeneGo Renews Its Agreement With Bayer Schering Pharma AG for Another Three Years
3. Micromet Enters Into Agreement for Solid Tumor BiTE Antibody with Bayer Schering Pharma AG
4. Stemedica Announces the Appointment of Dr. Michael Bayer as Director, Medical Services
5. Bayer CropScience Donates $1.1 Million to United Fresh Research & Education Foundation to Create the Center for Global Produce Sustainability
6. Bayer and Onyx Announce Nexavar Data Presentations at 45th American Society of Clinical Oncology Annual Meeting
7. Onyx Pharmaceuticals Files Complaint Against Bayer Corporation
8. Neptune Products to be commercialized by BAYER HealthCare
9. DuPont and Bayer CropScience Expand Collaboration With Broad License Agreements
10. Bayers CONTOUR and Bayers BREEZE2 Blood Glucose Monitoring Systems Do Not Use Problematic GDH-PQQ Technology
11. Bayer CropScience Announces Investment of $25 Million for Institute Site
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... ... August 03, 2015 , ... ... vacuum pumps to its comprehensive line of analytical laboratory equipment. With optimized features, ... versatile pumps provide a chemically resistant and maintenance-free solution for a broad range ...
(Date:7/31/2015)... , ... July 31, 2015 , ... ... the detection and quantification of partially hydrolyzed gluten in foods, has been accepted ... adopted the method “Partially Hydrolyzed Gluten in Fermented Cereal-Based Products by R5 Competitive ...
(Date:7/30/2015)... ... July 30, 2015 , ... Tronics, a designer ... & Marketing Director. , With more than 25 years of experience in ... Tronics’ business development activities worldwide. He brings to the company his strong expertise ...
(Date:7/30/2015)... , July 30, 2015   Aratana ... pet therapeutics company focused on the licensing, development ... animals, today announced that its strategic partner VetStem ... dose confirmation study of AT-016, an adipose-derived allogeneic ... the treatment of osteoarthritis pain in dogs. ...
Breaking Biology Technology:Sterlitech Launches New Line of Vacuum Pumps 2RIDASCREEN® Competitve Gliadin Receives AOAC Official First Action Status 2Tronics appoints Francois Vieillard as Sales and Marketing Director 2Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 2Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 3Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 4Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 5
... November 2, 2011 In preparation for ... Lupus drug in 50 years, Human Genome Sciences (HGS) ... its newly formed European commercial sales team. The company ... of use, flexibility, mobility, industry-specific functionality, speed, and low ...
... month,s edition of Physics World, Paul Blom and Ton ... a way of creating thin, flexible sheets of organic ... process. These bendable materials could oust the ... our surroundings, being used for everything from lighting tiles ...
... Inc., a California based biotech company, announced today ... from the United States Patent and Trademark Office ... (application 10/705,109).  The Notice allowed 17 claims for ... using libraries of antibodies.  This method has several ...
Cached Biology Technology:Human Genome Sciences Europe Moves to the Cloud With Veeva CRM to Support New Lupus Treatment 2Human Genome Sciences Europe Moves to the Cloud With Veeva CRM to Support New Lupus Treatment 3Researchers roll out a new form of lighting 2
(Date:7/31/2015)... Jul. 31, 2015 NXT-ID, Inc. (NASDAQ: NXTD ... focused on the growing mobile commerce market and creator ... filed provisional patent 62/198989 for ELECTRONIC CRYPTO-CURRENCY ... a method to advance crypto-currencies such as Bitcoin into ... common, uniform way to manage all payments.  ...
(Date:7/23/2015)... July 23, 2015 Aware, Inc. (NASDAQ: AWRE ... reported financial results for its second quarter ended June 30, ... 2015 was $4.5 million, a decrease of 33% compared to ... in the second quarter of 2015 was $0.3 million, or ... $0.04 per diluted share, in the same period a year ...
(Date:7/20/2015)... , July 20, 2015  Acuity Market Intelligence,s ... The Convergence of Commerce and Privacy" forecasts that ... biometric apps will be downloaded to smart mobile ... mobile biometrics market is projected to generate more ... during the seven-year forecast period.    ...
Breaking Biology News(10 mins):NXT-ID Patents Electronic Crypto-Currency Management Technology 2NXT-ID Patents Electronic Crypto-Currency Management Technology 3NXT-ID Patents Electronic Crypto-Currency Management Technology 4Aware, Inc. Reports Second Quarter 2015 Financial Results 2Aware, Inc. Reports Second Quarter 2015 Financial Results 3Aware, Inc. Reports Second Quarter 2015 Financial Results 4Aware, Inc. Reports Second Quarter 2015 Financial Results 5Aware, Inc. Reports Second Quarter 2015 Financial Results 6Biometrics on Smart Mobile Devices to Redefine Digital Identity with 12.9 Billion Biometric App Downloads between 2014 and 2020 2
... administered in combination with a short course of ... the most lethal form of the disease, according ... Institute of Infectious Diseases (USAMRIID). , In ... Institute of Allergy and Infectious Diseases (NIAID), investigators ...
... Insect Molecular Biology, today publishes its Honey Bee Genome ... the long-awaited Honey Bee Genome Sequence, published earlier this ... Genome Sequencing Project (HBGSP), a large scale communal project ... the National Human Genome Research Institute, is expected to ...
... 20 years studying a worm-shaped parasite too small to ... Hussey and his research team have found a way ... world's most destructive groups of plant pathogens. , Root-knot ... nematodes worldwide, said Hussey, a distinguished research professor in ...
Cached Biology News:Vaccine combined with short-term postexposure antibiotics protects monkeys from inhalational anthrax 2Vaccine combined with short-term postexposure antibiotics protects monkeys from inhalational anthrax 3Looking to a new era in bee research 2UGA scientists engineer root-knot nematode resistance 2
Vented Caps for 75 cm2 Flasks...
I-Ab MHC Class II...
... ProteinChip System, Series 4000 incorporates the critical ... and biologists in biomarker research. The Series ... route for converting biomarker discoveries to biomarker ... Series 4000 is designed to fit into ...
...
Biology Products: